References
- Jones GL, Will A, Jackson GH, et al. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2015;169:661–671.
- Annemans L, Moeremans K, Lamotte M, et al. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support Care Cancer. 2003;11:249–257.
- Wössmann W, Schrappe M, Meyer U, et al. Incidence of tumor lysis syndrome in children with advanced stage Burkitt’s lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol. 2003;82:160–165.
- Wilson FP, Berns JS. Tumor lysis syndrome: new challenges and recent advances. Adv Chronic Kidney Dis. 2014;21:18–26.
- Coiffier B, Altman A, Pui C-H, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. JCO. 2008;26:2767–2778.
- Held-Warmkessel J. Preventing & managing tumor lysis syndrome. Oncol Times. 2010;32:1–7.
- Alakel N, Middeke JM, Schetelig J, et al. Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase. OTT. 2017;10:597–605. 10.2147/OTT.S103864
- Chu M, Zhang T, Yao X, et al. The current status and disease burden of pediatric tumor lysis syndrome, published in the 23rd Pediatric Conference of the Chinese Medical Association, 2018, October 27–28, Xiamen, China.
- ELITEK (rasburicase) for injection, for intravenous use Initial U.S. Sanofi. 2002.
- Zhengren H. Acute tumor lysis syndrome (analysis of 130 cases). J Clin Hematol. 2005;18:52–54.
- Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001;97:2998–3003.
- Yeh JM, Hanmer J, Ward ZJ, et al. Chronic conditions and utility-based health-related quality of life in adult childhood cancer survivors. J Natl Cancer Inst. 2016;108:2016–2019.
- Commission of Macroeconomics and Health. Macroeconomics and health: investing in health for economic development. Rev Panam Salud Pública. 2002;12:143–144.